Literature DB >> 26017469

Mid-term clinical and echocardiographic evaluation of super responders with and without pacing: the preliminary results of a prospective, randomized, single-centre study.

Serkan Cay1, Ozcan Ozeke2, Firat Ozcan2, Dursun Aras2, Serkan Topaloglu2.   

Abstract

AIMS: Super response to cardiac resynchronization therapy (CRT) is related to excellent long-term prognosis. However, it is not known whether super responders (SRs) are in remission or have made a complete recovery. In other words, is CRT a destination therapy or a bridge to recovery? The objective was to assess the evolution of the clinical and echocardiographic data of SRs without pacemaker activity at the mid-term follow-up. METHODS AND
RESULTS: A total of 19 SRs were randomly assigned to a deactivated pacemaker function (Off-Pace group) or a continued pacemaker activity (On-Pace group). Clinical and echocardiographic parameters were evaluated before implantation, at randomization, and after 6 and 12 months of this randomization. Patients assigned to the Off-Pace group deteriorated in terms of the New York Heart Association class (from 1.3 ± 0.5 to 2.4 ± 0.7), 6-min walk distance (from 569 ± 68 to 343 ± 162 m), and echocardiographic data, including left ventricular ejection fraction (from 55 ± 3 to 36 ± 12%), left ventricular end-systolic volume (from 61 ± 10 to 117 ± 36 mL), left ventricular end-diastolic diameter (from 53 ± 3 to 61 ± 6 mm), and left ventricular end-systolic diameter (from 40 ± 3 to 53 ± 8 mm) at 12 months, whereas no change was observed in the On-Pace group. Turning off the pacemaker function was also related to hospitalization for heart failure and appropriate cardioverter-defibrillator device intervention.
CONCLUSION: Super responders without pacing had poor clinical and echocardiographic outcomes at the mid-term follow-up. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac resynchronization therapy; Deactivation; Outcome; Super response

Mesh:

Year:  2015        PMID: 26017469     DOI: 10.1093/europace/euv129

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

1.  Plasticity of left ventricular function with cardiac resynchronization therapy.

Authors:  Hong-Xia Niu; Yi-Ran Hu; Wei Hua; Min Gu; Jing Wang; Michael R Gold; Shu Zhang
Journal:  J Interv Card Electrophysiol       Date:  2019-05-28       Impact factor: 1.900

Review 2.  Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.

Authors:  Tomas Hnat; Josef Veselka; Jakub Honek
Journal:  ESC Heart Fail       Date:  2022-04-18

3.  Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy.

Authors:  Min Gu; Han Jin; Wei Hua; Xiao-Han Fan; Hong-Xia Niu; Tao Tian; Li-Gang Ding; Jing Wang; Cong Xue; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2017-04       Impact factor: 3.327

4.  Biventricular Pacing Going Along with Acute Hemodynamic Response in a Patient with Huge Anterior Wall Aneurysm - Importance of Pacing Viable Myocardium.

Authors:  Spyridon Liosis; Evgeny Lyan; Amr Abdin; Ben Brüggemann; Stefan A Lange; Julia Vogler; Christian H Heeger; Kivanc Yalin; Roland R Tilz; Charlotte Eitel
Journal:  Am J Case Rep       Date:  2019-06-09

5.  Echocardiographic markers of dyssynchrony as predictors of super-response to cardiac resynchronisation therapy - a pilot study.

Authors:  V A Kuznetsov; A M Soldatova; J D Kasprzak; D V Krinochkin; N N Melnikov
Journal:  Cardiovasc Ultrasound       Date:  2018-10-02       Impact factor: 2.062

6.  Cardiac electrical and mechanical synchrony of super-responders to cardiac resynchronization therapy.

Authors:  Ke-Bei Li; Zhi-Yong Qian; Xue-Song Qian; Yong Zhou; Di-Di Zhu; Yuan-Hao Qiu; Yao Wang; Xiao-Feng Hou; Jian-Gang Zou; Yu-Feng Sheng
Journal:  Chin Med J (Engl)       Date:  2020-01-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.